Several large drugmakers including Merck & Co Inc and Pfizer Inc on Thursday unveiled a $1 billion (790 million pounds) fund to bolster struggling antibiotic companies and sustain a pipeline for new treatments.
July 9 A new $1 billion fund backed by 20
drugmakers including Merck & Co Inc and Pfizer Inc
is aiming to bolster struggling antibiotic companies and
sustain a pipeline for new treatments, an industry group said on
Aimmune Therapuetics Inc said its peanut allergy drug, whose launch had been paused because of coronavirus lockdowns, is again being administered to patients as allergy specialists reopen, the drugmaker's executives told Reuters on Thursday.
The U.S. Food and Drug Administration has approved more than 30 new drugs since January. So far, five medicines have seen their commercial launches delayed by manufacturers until later in the year or 2021 because of the COVID-19 pandemic.
Treatments for peanut allergy and Parkinson's disease are among U.S. drug launches that have been postponed by the COVID-19 pandemic as drugmakers struggle with disruptions to business, a Reuters review of filings and interviews with executives show.
An experimental coronavirus vaccine developed by Inovio Pharmaceuticals Inc showed promise and was found to be safe in an early-stage human trial, the company said on Tuesday.
June 26 Vaxart Inc said on Friday it
would test its experimental oral COVID-19 vaccine on monkeys
infected with the new coronavirus in a study funded by the Trump
administration's vaccine-acceleration program called "Operation
PARIS French drugmaker Sanofi has agreed a potential $2 billion (£1.6 billion) vaccines deal with Translate Bio , expanding their collaboration in development of an inoculation against COVID-19 and sending the U.S. biotech company's shares soaring.